Erik S G Stroes Selected Research

mipomersen

11/2014	Liver histology during Mipomersen therapy for severe hypercholesterolemia.
8/2013	Is mipomersen ready for clinical implementation? A transatlantic dilemma.
5/2012	Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.
8/2010	Apolipoprotein B synthesis inhibition: results from clinical trials.
5/2010	Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
5/2010	Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Erik S G Stroes Research Topics

Disease

55	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 12/2002
40	Atherosclerosis 12/2021 - 03/2004
35	Inflammation (Inflammations) 01/2022 - 04/2005
23	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 10/2004
19	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022 - 12/2002
13	Atherosclerotic Plaque (Atheroma) 01/2022 - 02/2006
9	Neoplasms (Cancer) 12/2022 - 07/2007
8	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 01/2009
7	Myocardial Infarction 01/2022 - 02/2012
7	Coronary Disease (Coronary Heart Disease) 10/2020 - 12/2009
6	Aortic Valve Stenosis (Aortic Stenosis) 01/2022 - 01/2019
6	Rheumatoid Arthritis 01/2022 - 06/2007
6	Hypercholesterolemia 01/2022 - 04/2007
6	Injection Site Reaction 01/2021 - 08/2007
6	Type 2 Diabetes Mellitus (MODY) 11/2020 - 11/2007
4	Body Weight (Weight, Body) 12/2020 - 05/2007
4	Carotid Artery Diseases 10/2020 - 04/2008
4	Obesity 09/2018 - 09/2008
4	Pathologic Constriction (Stenosis) 01/2016 - 09/2005
4	Hypoalphalipoproteinemias (Hypoalphalipoproteinemia) 12/2014 - 06/2003
4	Hypertension (High Blood Pressure) 01/2011 - 12/2001
4	Hyperplasia 09/2005 - 02/2004
3	Peripheral Arterial Disease 01/2022 - 12/2013
3	Pancreatitis 01/2021 - 03/2018
3	Arteritis 01/2021 - 10/2014
3	Stroke (Strokes) 10/2020 - 02/2012
3	Chronic Disease (Chronic Diseases) 01/2020 - 12/2012
3	Insulin Resistance 10/2017 - 07/2007
3	Thrombosis (Thrombus) 08/2016 - 07/2009
3	Vascular Diseases (Vascular Disease) 01/2013 - 07/2007
2	Aortic Valve Disease 01/2022 - 01/2020
2	Ischemic Stroke 12/2021 - 01/2021
2	Homozygous Familial Hypercholesterolemia 01/2021 - 08/2013
2	Chronic Renal Insufficiency 01/2021 - 01/2017
2	Angioedema 01/2020 - 04/2019
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 04/2006
2	Hereditary Angioedemas 01/2020 - 12/2008
2	Myocardial Ischemia (Ischemic Heart Diseases) 12/2019 - 06/2007
2	Disease Progression 01/2019 - 01/2019
2	Hypertriglyceridemia 03/2018 - 12/2014
2	Endotoxemia 01/2018 - 01/2013
2	Hypotension (Low Blood Pressure) 12/2011 - 10/2007

Drug/Important Bio-Agent (IBA)

32	LipidsIBA 10/2021 - 06/2004
29	LDL CholesterolIBA 01/2022 - 06/2004
26	Lipoprotein(a)IBA 01/2022 - 06/2004
24	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 12/2002
22	oxidized low density lipoproteinIBA 01/2022 - 02/2007
22	HDL CholesterolIBA 01/2022 - 06/2004
17	Triglycerides (Triacylglycerol)IBA 12/2021 - 06/2004
14	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2002
14	CholesterolIBA 01/2021 - 06/2004
13	Lipoproteins (Lipoprotein)IBA 12/2021 - 06/2004
12	C-Reactive ProteinIBA 01/2022 - 06/2004
11	Apolipoproteins B (ApoB)IBA 01/2021 - 05/2007
11	ApolipoproteinsIBA 01/2019 - 05/2007
9	HDL LipoproteinsIBA 12/2022 - 05/2007
9	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2019 - 10/2004
7	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021 - 02/2007
7	Proteins (Proteins, Gene)FDA Link 11/2020 - 12/2010
7	Pharmaceutical PreparationsIBA 01/2020 - 02/2015
6	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 12/2022 - 10/2016
6	mipomersenIBA 11/2014 - 05/2010
5	Glucose (Dextrose)FDA LinkGeneric 12/2022 - 06/2004
5	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022 - 08/2016
4	Apolipoprotein C-IIIIBA 01/2020 - 12/2014
4	Simvastatin (Zocor)FDA LinkGeneric 04/2015 - 12/2002
4	Polytetrafluoroethylene (Teflon)FDA Link 09/2005 - 02/2004
3	8- hydroxy- 2,2,14,14- tetramethylpentadecanedioic acidIBA 01/2022 - 01/2019
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 03/2012
3	Apolipoproteins E (ApoE)IBA 01/2021 - 04/2015
3	CalciumIBA 01/2020 - 03/2012
3	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2019 - 11/2005
3	Apolipoprotein B-100 (Apo B 100)IBA 01/2019 - 05/2010
3	evolocumabIBA 01/2019 - 10/2017
3	EndotoxinsIBA 01/2018 - 05/2007
3	Cholesterol Ester Transfer ProteinsIBA 07/2009 - 09/2005
2	InterleukinsIBA 01/2022 - 03/2014
2	Ezetimibe (Zetia)FDA Link 01/2021 - 04/2008
2	Atorvastatin (Lipitor)FDA Link 01/2021 - 10/2016
2	ISIS 304801IBA 01/2021 - 01/2019
2	Chemokine ReceptorsIBA 01/2021 - 03/2018
2	evinacumabIBA 01/2021 - 12/2020
2	CytokinesIBA 12/2020 - 01/2018
2	CER-001IBA 10/2020 - 01/2016
2	Butyrates (Butyrate)IBA 01/2020 - 01/2016
2	LDL Receptors (LDL Receptor)IBA 01/2019 - 07/2013
2	LigandsIBA 01/2018 - 07/2010
2	Prednisolone (Predate)FDA LinkGeneric 01/2016 - 01/2016
2	dalcetrapibIBA 12/2014 - 07/2009
2	ATP-Binding Cassette Transporters (ABC Transporters)IBA 12/2014 - 01/2013
2	Phosphatidylcholine-Sterol O-Acyltransferase (Lecithin Cholesterol Acyltransferase)IBA 08/2014 - 12/2011
2	lipoprotein cholesterolIBA 12/2011 - 10/2007

Therapy/Procedure

35	Therapeutics 12/2022 - 12/2002
4	Renal Dialysis (Hemodialysis) 07/2009 - 02/2004
3	Blood Component Removal (Apheresis) 01/2021 - 10/2014
2	Injections 01/2021 - 01/2014
2	Fecal Microbiota Transplantation 01/2018 - 10/2017
2	Biological Therapy 12/2016 - 01/2016
2	Stents 01/2015 - 03/2005
2	Secondary Prevention 09/2012 - 02/2008